Literature DB >> 26275872

Changes in presepsin concentrations in surgical patients with end-stage kidney disease undergoing living kidney transplantation: a pilot study.

Junichi Saito1, Eiji Hashiba2, Tetsuya Kushikata3, Akio Mikami4, Kazuyoshi Hirota5.   

Abstract

Presepsin is a useful marker for differentiating sepsis from non-infection-related systemic inflammatory response syndrome. There are data describing elevated presepsin concentrations in patients with kidney dysfunction even in the absence of sepsis, but corresponding data for patients with end-stage kidney disease (ESKD) undergoing living kidney transplantation (LKT) are lacking. We investigated the changes in presepsin concentrations in this patient group in order to elucidate any relationship with renal function. Written informed consent was obtained from patients with ESKD requiring hemodialysis who underwent LKT from June 2014 through March 2015 at Hirosaki University Hospital. Patients with obvious signs of infection were excluded. Perioperative presepsin and procalcitonin concentrations were measured before induction of anesthesia, on admission to the intensive care unit after surgery, and on postoperative day (POD) 1 and POD 2. Preoperative presepsin concentration was markedly higher than the upper limit of normal in patients with ESKD (1252 ± 451 pg/mL). Presepsin concentrations consistently decreased after LKT. Moreover, presepsin concentration was strongly correlated with serum creatinine (r (2) = 0.72, n = 24, p < 0.001). These data suggest that the kidney clearly plays an important role in the metabolism and excretion of presepsin.

Entities:  

Keywords:  End-stage kidney disease; Living kidney transplantation; Presepsin; Procalcitonin

Mesh:

Substances:

Year:  2015        PMID: 26275872     DOI: 10.1007/s00540-015-2065-1

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  11 in total

1.  The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function.

Authors:  M Meisner; T Lohs; E Huettemann; J Schmidt; M Hueller; K Reinhart
Journal:  Eur J Anaesthesiol       Date:  2001-02       Impact factor: 4.330

2.  Development of a point-of-care assay system for measurement of presepsin (sCD14-ST).

Authors:  Yoshikazu Okamura; Hiroyuki Yokoi
Journal:  Clin Chim Acta       Date:  2011-08-03       Impact factor: 3.786

Review 3.  Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis.

Authors:  H Tang; T Huang; J Jing; H Shen; W Cui
Journal:  Infection       Date:  2009-10-13       Impact factor: 3.553

4.  Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome.

Authors:  Tatsuyori Shozushima; Gaku Takahashi; Naoya Matsumoto; Masahiro Kojika; Yoshikazu Okamura; Shigeatsu Endo
Journal:  J Infect Chemother       Date:  2011-05-12       Impact factor: 2.211

5.  Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial.

Authors:  Serge Masson; Pietro Caironi; Caterina Fanizza; Ralf Thomae; Roberto Bernasconi; Andrea Noto; Roberto Oggioni; Giovanni Stefano Pasetti; Marilena Romero; Gianni Tognoni; Roberto Latini; Luciano Gattinoni
Journal:  Intensive Care Med       Date:  2014-10-16       Impact factor: 17.440

6.  Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study.

Authors:  Shigeatsu Endo; Yasushi Suzuki; Gaku Takahashi; Tatsuyori Shozushima; Hiroyasu Ishikura; Akira Murai; Takeshi Nishida; Yuhei Irie; Masanao Miura; Hironobu Iguchi; Yasuo Fukui; Kimiaki Tanaka; Tsuyoshi Nojima; Yoshikazu Okamura
Journal:  J Infect Chemother       Date:  2012-06-13       Impact factor: 2.211

7.  Monocyte cell-surface CD14 expression and soluble CD14 antigen in hemodialysis: evidence for chronic exposure to LPS.

Authors:  W A Nockher; J E Scherberich
Journal:  Kidney Int       Date:  1995-11       Impact factor: 10.612

8.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012.

Authors:  R P Dellinger; Mitchell M Levy; Andrew Rhodes; Djillali Annane; Herwig Gerlach; Steven M Opal; Jonathan E Sevransky; Charles L Sprung; Ivor S Douglas; Roman Jaeschke; Tiffany M Osborn; Mark E Nunnally; Sean R Townsend; Konrad Reinhart; Ruth M Kleinpell; Derek C Angus; Clifford S Deutschman; Flavia R Machado; Gordon D Rubenfeld; Steven Webb; Richard J Beale; Jean-Louis Vincent; Rui Moreno
Journal:  Intensive Care Med       Date:  2013-01-30       Impact factor: 17.440

Review 9.  Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.

Authors:  Rinaldo Bellomo; Claudio Ronco; John A Kellum; Ravindra L Mehta; Paul Palevsky
Journal:  Crit Care       Date:  2004-05-24       Impact factor: 9.097

10.  Usefulness of presepsin in the diagnosis of sepsis in patients with or without acute kidney injury.

Authors:  Yoshihiko Nakamura; Hiroyasu Ishikura; Takeshi Nishida; Yasumasa Kawano; Rie Yuge; Reiko Ichiki; Akira Murai
Journal:  BMC Anesthesiol       Date:  2014-10-04       Impact factor: 2.217

View more
  3 in total

1.  Sepsis and the orexin system.

Authors:  Kazuyoshi Hirota
Journal:  J Anesth       Date:  2016-08-31       Impact factor: 2.078

2.  Prediction of Postoperative Sepsis Based on Changes in Presepsin Levels of Critically Ill Patients with Acute Kidney Injury after Abdominal Surgery.

Authors:  Chang Hwan Kim; Eun Young Kim
Journal:  Diagnostics (Basel)       Date:  2021-12-09

3.  Usefulness of presepsin for the early detection of infectious complications after elective colorectal surgery, compared with C-reactive protein and procalcitonin.

Authors:  Erika Amanai; Kishiko Nakai; Junichi Saito; Eiji Hashiba; Takuya Miura; Hajime Morohashi; Yoshiyuki Sakamoto; Akio Mikami; Kenichi Hakamada; Kazuyoshi Hirota
Journal:  Sci Rep       Date:  2022-03-10       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.